金花股份(600080.SH):擬以1418萬元將重藥陝西公司8.39%股權轉讓給陝西祥灃
格隆匯9月8日丨金花股份(600080.SH)公佈,公司擬將所持有的參股公司重藥陝西公司8.39%股權轉讓給陝西祥灃,交易價格以目標公司2022年度審計報吿確認的淨資產為作價依據,經雙方協商確定交易金額為1418萬元。本次交易基於公司整體戰略佈局,進一步優化公司業務結構,有利於公司集中資源優勢,聚焦主業發展,提高公司資產運營效率,促進公司長遠發展,符合公司和全體股東利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.